Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| STAAR SURGIC | STAA | 10.98% |
| DTS INC | DTSI | 6.89% |
| ANIKA THERAP | ANIK | 6.04% |
| LUMOS NETWOR | LMOS | 5.70% |
| INSTEEL IND | IIIN | 5.28% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
The QE question will again be on many investors’ minds today as Ben Bernanke testifies before the Senate Banking committee. Positive earnings reports from Goldman Sachs (GS - Analyst Report) and Coca Cola (KO - Analyst Report) and a slew economic reports provide the backdrop for today’s trading action.
Monday’s surprisingly weak Retail Sales report provided further confirmation of economic softness that the back-to-back weak monthly jobs reports have been showing lately. In prior episodes of economic weakness – the economy went through such phases in the Spring/Summer months in 2011 and 2010 – the Fed would save the day by implementing monetary easing.
And that’s what the market is clamoring for this time around as well. The Fed did come through partly on that count by extending Operation Twist through the end of the year, but the market wants a fresh round of QE.
Bernanke is not going to announce QE in today’s testimony and nobody expects him to do that. But the market will view Bernanke’s emphasis on ‘downside risks’ to the economy in favorable light. The expectation is that Bernanke will come across as dovish in his comments and may be even discuss some of the policy tools at the Fed’s disposal to stimulate the economy.
With inflation effectively a non-issue, as today’s June CPI report shows, and all key economic indicators pointing down, many expect the Fed to come through with more easing in its meeting next month. How effective more easing will be in terms of desirable economic outcomes is an altogether different issue. And on that score, many doubt if more QE can do any good given the domestic fiscal issues and global growth concerns.
Bernanke and economic reports aside, we have entered the thick of the second quarter earnings season, with this morning’s basket of reports generally in the positive category. We got a solid earnings and revenue beat from Goldman Sachs despite difficult market conditions.
Coca-Cola also came out of expectations on volume strength, though Johnson & Johnson’s (JNJ - Analyst Report) revenue and guidance were short of expectations, likely due to currency translation issues. We have Intel (INTC - Analyst Report) and Yahoo (YHOO - Analyst Report) report after the close today.
RELATED ARTICLES(This article was originally published as Ahead of Wall Street - July 17, 2012.)
A Flood of Earnings
When Fed QE Goes Bust
A Very Weak Start to Q2 Earnings Season
Get the full Analyst Report on YHOO - FREE
Get the full Analyst Report on KO - FREE
Get the full Analyst Report on JNJ - FREE
Get the full Analyst Report on INTC - FREE
Get the full Analyst Report on GS - FREE